576 results on '"Maelandsmo, Gunhild M"'
Search Results
2. The expression pattern of pyruvate dehydrogenase kinases predicts prognosis and correlates with immune exhaustion in clear cell renal cell carcinoma
3. Strategies to inhibit FGFR4 V550L-driven rhabdomyosarcoma
4. Correlation of expression of Major Vault Protein with androgen receptor and immune checkpoint protein B7-H3, and with poor prognosis in prostate cancer
5. Identification of a core EMT signature that separates basal-like breast cancers into partial- and post-EMT subtypes
6. Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer
7. Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft
8. Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers
9. Metabolic re-wiring of isogenic breast epithelial cell lines following epithelial to mesenchymal transition
10. Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
11. Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
12. Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer
13. Supplementary Table S1 from Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain
14. Abstract 5627: Spatial protein profiling by cyclic immunofluorescence to interpret and improve bulk tumor-based predictor of response to chemotherapy with bevacizumab in neoadjuvant breast cancer treatment
15. Abstract 4675: Chemoresistant patient-derived xenografts to identify treatment options in breast cancer patients not responding to standard chemotherapy
16. Data from A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases
17. Supplementary Figures S1-3 from A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases
18. Data from Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain
19. Supplementary File S1 from A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases
20. Supplementary Data incl Figure S1 and Table S3 from Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain
21. Supplementary Table 1 from Proteomic Characterization of Breast Cancer Xenografts Identifies Early and Late Bevacizumab-Induced Responses and Predicts Effective Drug Combinations
22. Data from Proteomic Characterization of Breast Cancer Xenografts Identifies Early and Late Bevacizumab-Induced Responses and Predicts Effective Drug Combinations
23. Supplementary Table 3 from Proteomic Characterization of Breast Cancer Xenografts Identifies Early and Late Bevacizumab-Induced Responses and Predicts Effective Drug Combinations
24. Supplementary Table 2 from Proteomic Characterization of Breast Cancer Xenografts Identifies Early and Late Bevacizumab-Induced Responses and Predicts Effective Drug Combinations
25. Data from The Mitogen-Activated Protein Kinase Phosphatase Vaccinia H1–Related Protein Inhibits Apoptosis in Prostate Cancer Cells and Is Overexpressed in Prostate Cancer
26. Supplementary Table 1 from STAMP1 Is Both a Proliferative and an Antiapoptotic Factor in Prostate Cancer
27. Supplementary Figure 5 from The Mitogen-Activated Protein Kinase Phosphatase Vaccinia H1–Related Protein Inhibits Apoptosis in Prostate Cancer Cells and Is Overexpressed in Prostate Cancer
28. Data from STAMP1 Is Both a Proliferative and an Antiapoptotic Factor in Prostate Cancer
29. Supplementary Figure 7 from The Mitogen-Activated Protein Kinase Phosphatase Vaccinia H1–Related Protein Inhibits Apoptosis in Prostate Cancer Cells and Is Overexpressed in Prostate Cancer
30. Supplementary Figure Legends 1-7 from The Mitogen-Activated Protein Kinase Phosphatase Vaccinia H1–Related Protein Inhibits Apoptosis in Prostate Cancer Cells and Is Overexpressed in Prostate Cancer
31. Supplementary Figure 3 from The Mitogen-Activated Protein Kinase Phosphatase Vaccinia H1–Related Protein Inhibits Apoptosis in Prostate Cancer Cells and Is Overexpressed in Prostate Cancer
32. Supplementary Figure 6 from The Mitogen-Activated Protein Kinase Phosphatase Vaccinia H1–Related Protein Inhibits Apoptosis in Prostate Cancer Cells and Is Overexpressed in Prostate Cancer
33. Supplementary Figure 1 from The Mitogen-Activated Protein Kinase Phosphatase Vaccinia H1–Related Protein Inhibits Apoptosis in Prostate Cancer Cells and Is Overexpressed in Prostate Cancer
34. The expression pattern of pyruvate dehydrogenase kinases predicts prognosis and correlates with immune exhaustion in clear cell renal cell carcinoma
35. Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer
36. p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance
37. A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases
38. Metabolic reprogramming supports the invasive phenotype in malignant melanoma
39. Dynamic 2-Deoxy-2-[18F]Fluoro-D-Glucose Positron Emission Tomography for Chemotherapy Response Monitoring of Breast Cancer Xenografts
40. Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases
41. Corrigendum to “Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft”, [Journal of Control Release, 293 (2019) 183–192]
42. Synthesis, characterization, and cellular uptake of magnetic nanocarriers for cancer drug delivery
43. Metastasis-associated protein S100A4 induces a network of inflammatory cytokines that activate stromal cells to acquire pro-tumorigenic properties
44. Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease
45. Enrichment of nuclear S100A4 during G2/M in colorectal cancer cells: possible association with cyclin B1 and centrosomes
46. Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer – the MetAction precision medicine study
47. Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer
48. Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trial
49. pH-Responsive Nano Carriers for Doxorubicin Delivery
50. STAMP2 increases oxidative stress and is critical for prostate cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.